The U.S. Environmental Protection Agency's (EPA) Office of Pesticide Programs (OPP) estimated that 891 pesticide active ingredients were registered in 1997 ([@b6-ehp0114-000010]) and that 888 million pounds of pesticide active ingredients were used in the United States in 2001 ([@b44-ehp0114-000010]). Few of these chemicals are applied alone but rather are applied in formulations using different combinations of several pesticide active ingredients ([@b50-ehp0114-000010]). It is not uncommon for many classes of pesticides, such as insecticides, herbicides, and fungicides, to be used on the same crop ([@b54-ehp0114-000010]). In the case of insecticides, an adjuvant is often added to the formulations to enhance the intensity of the lethal effect. In the case of herbicides, due to the increasing incidence of plant tolerance to a specific pesticide, some formulations now have as many as three active ingredients ([@b50-ehp0114-000010]). Each active ingredient has a specific mode of action for controlling a pest, and each active ingredient has its own possible side effects on the wildlife and humans exposed to it. It is impossible to determine the cumulative risk posed to wildlife and humans as the result of releasing vast amounts of pesticide mixtures into the environment.

The quality and quantity of the data about the risk posed to humans by individual pesticides vary considerably. In some instances there are numerous studies about the health effects of a particular pesticide in humans and laboratory animals, and for others there are very few. In general, the longer the active ingredient has been on the market, the greater the number of citations in the peer-reviewed literature. Data are sparse when linking pesticides with neurodevelopmental effects other than for the insecticides chlorpyrifos (CPF), parathion, and 1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)ethane (DDT).

Unlike obvious structural defects, most neurodevelopmental effects cannot be seen at birth or even later in life. Instead, adverse effects on the nervous system are expressed in terms of how an individual behaves or functions. Behavior and function vary considerably from birth through adulthood. Functional deficits are not "on" and "off" conditions but instead range from inconsequential through very mild to very severe to totally debilitating. Consequently, it is difficult to quantify neuro-developmental impairment. Some of the end points used in the laboratory to detect functional impairment of the brain and nervous system are measured at the gene, cell, biochemical, and/or physiologic levels and often require high-tech instrumentation to quantify. At the human level, a battery of tests is continuing to evolve to measure with increasing sensitivity psychomotor, psychologic, clinical, and psychiatric symptoms to better quantify functional impairment.

In this article I have two principal purposes in discussing the inherent risks of using pesticides, the limitations of testing techniques, and the intrinsic incompleteness of all scientific evidence: *a*) to encourage the use of the open literature about the neurodevelopmental effects of all classes of pesticides when setting the criteria for determining their safety and *b*) to encourage a more rigorous regulatory approach to protect human and environmental health in the absence of complete scientific certainty. I begin by presenting unequivocal evidence of pesticide exposure to numerous classes of pesticides during development. This is followed by a section on human epidemiology where only weak data are available linking neuro-developmental impairment with pesticides. Next, I present a case study of how CPF cryptically interferes with brain development one stage after another. This is followed with selected laboratory studies demonstrating that other insecticides as well as other pesticide classes target prenatal brain development similar to CPF and share similar and sometimes diverse impacts on the construction and function of the brain. As the data reveal, not only insecticides but other classes of pesticides, such as herbicides and fungicides, can also interfere with neurodevelopment. In the "Discussion" I challenge the protective value of current pesticide risk assessment strategies in light of the vast numbers of pesticide products on the market with untold numbers of targets and mechanisms of action that can cause neurodevelopmental damage.

Evidence of Exposure to Pesticides
==================================

Improvements in analytical laboratory equipment and testing procedures have made it easier to detect pesticides and their metabolites at very low concentrations in almost all human tissue. From routinely detecting parts per million (milligrams per kilogram) and more recently to as low as parts per trillion (picograms per kilogram), some laboratories are now able to measure concentrations down to parts per quintillion (femtograms per kilogram). The development of noninvasive sampling methods, such as testing for pesticides and their metabolites in urine, has made it possible to monitor pesticide exposure in infants and children. It is fairly safe to say that every child conceived today in the Northern hemisphere is exposed to pesticides from conception throughout gestation and lactation regardless of where it is born. The herbicide 2,4-dichlorophenoxyacetic acid (2,4--D) was found in approximately 50% of semen samples provided by 97 Ontario, Canada, farmers ([@b5-ehp0114-000010]). The herbicides atrazine, metolachlor, alachlor, and 2,4--D and the insecticides diazinon and the CPF analyte 3,5,6-trichloro-2-pyridinol (TCP) were found in semen of men in central Missouri and in urban Minneapolis, Minnesota ([@b79-ehp0114-000010]); the insecticides chlordane, dichloro-diphenyldichloroethylene (DDE), heptachlor epoxide, and hexachlorobenzene (HCB) were found in ovarian follicular fluid from women undergoing *in vitro* fertilization in Halifax, Hamilton, and Vancouver, Canada ([@b41-ehp0114-000010]); hexachlorocyclohexane and *p,p*′-DDE were found in amniotic fluid of women undergoing routine amniocentesis in Los Angeles, California ([@b31-ehp0114-000010]); and nonpersistent pesticides were found in the amniotic fluid of women referred for amniocentesis in the agricultural San Joaquin Valley, California ([@b13-ehp0114-000010]). Pesticides were also found in maternal blood, placental, and umbilical cord blood from women experiencing normal births and stillbirths in India ([@b69-ehp0114-000010]), from urban and rural mothers during Caesarian section in the Atoya River basin, Nicaragua ([@b25-ehp0114-000010]), and from mothers delivering normal and subnormal weight babies ([@b72-ehp0114-000010]). In addition, pesticides were found in the breast milk of mothers who delivered by Caesarian section in Nicaragua ([@b25-ehp0114-000010]), native Alaskan mothers living an indigenous lifestyle ([@b73-ehp0114-000010]), and women living in southwest Greece ([@b70-ehp0114-000010]). A median of 8.26 μg/mL CPF (range, 0.40--458.04 μg/mL) was discovered in the meconium of newborns in Manila, Philippines ([@b55-ehp0114-000010]). Six organo-phosphate (OP) pesticide metabolites were found in the meconium of 20 newborns in New York City ([@b81-ehp0114-000010]). The babies' first bowel movements held concentrations 10--100 times higher than their cord blood. One metabolite, diethylthiophosphate, was found in all 20 samples; another, diethyl-phosphate, was found in 19 of 20 samples. Both are metabolites of diazinon, CPF, and several other OP insecticides.

An eastern Washington State research team surveyed OP metabolites in the urine of 210 farmworkers and their children and in dust from their homes and vehicles ([@b20-ehp0114-000010]). They segregated farm chores into several classes: harvesting and picking, thinning, loading, transplanting, and pruning. Azinphosmethyl, an OP, was more often found in dust in thinners' homes (92.1% vs. 72.7%) and vehicles (92.6% vs. 76.5%) than in those of workers who did no thinning. Thinners' children had higher concentrations of OP metabolites in their urine, and the metabolites were found more frequently in the children (91.9% detectable in urine), compared to the adults (81.3% detectable; *p* = 0.002).

In Seattle, Washington, investigators measured five OP metabolites in 24-hr urine samples of preschool children (2--5 years of age) who were raised on either a predominantly organic (*n* = 18) or predominantly conventional diet (*n* = 21) ([@b22-ehp0114-000010]). Pesticide use was also recorded for each home. Median total dimethylphosphate metabolites (0.06 μmol/L) were significantly higher than median total diethyl alkylphosphates (0.02 μmol/L; *p* = 0.0001) in the urine. Those children on a conventional diet had levels of dimethylphosphate metabolites six times higher than those of children on an organic diet (medians = 0.17 and 0.03 μmol/L, respectively; *p* = 0.0003). Median concentrations of both metabolites were almost an order of magnitude higher in the conventionally fed children (0.34 μmol/L vs. 0.04 μmol/L). There were no age differences in the children in the two groups. Home use of pesticides varied, with seven conventional-diet families using OPs versus three organic-diet families using OPs. Although the study group was small and there were difficulties collecting urine samples, this research provides the first empirical data comparing urinary levels of pesticides in youngsters consuming predominantly organic versus conventional diets.

Human Epidemiology
==================

Determining a link between fetal exposure to a specific chemical and long-term expression of a change in health poses a monumental challenge when designing epidemiologic studies. For example, one human epidemiologic study uncovered weak but statistically significant associations between neurodevelopmental impairment as a result of exposure to two pesticides during gestation. In a large study of live births (*n* = 1,532), including 536 children fathered by pesticide applicators, [@b35-ehp0114-000010] discovered that "adverse neurologic and neurobehavioral developmental effects clustered among the children born to applicators of the fumigant phosphine \[odds ratio (OR) = 2.48; 95% confidence interval (CI), 1.2--5.1\]." They also discovered an OR for the herbicide glyphosate (Roundup) of 3.6 (95% CI, 1.3--9.6). Among the children in the phosphine group (*n* = 290), two were diagnosed with autism, which is high compared with the prevalence nationwide, and five were diagnosed with attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD). It took years of close interaction with the families in this study to be able to track their pesticide exposure without having to resort to recall and to follow the children's functional development (Garry VF, personal communication). The investigators were cautious about their findings and asked for confirmation.

Another study suggests that CPF might have an effect on head circumference related to the activity of paraoxonase (PON1), an enzyme that can detoxify CPF before it can inhibit acetylcholinesterase ([@b9-ehp0114-000010]). Babies with a small reduction in head circumference were from mothers whose TCP concentrations were above the detection limit, and their PON1 activity was in the lowest tertile (*p* = 0.014). Mothers and their infants (*n* = 404) were recruited from East Harlem and other sections of New York City.

In a more recent study, [@b82-ehp0114-000010] looked at the relationship between maternal OP urine metabolites and infant neuro-development. They employed a battery of tests using the Brazelton Neonatal Behavioral Assessment Scale for habituation, orientation, motor performance, range of state, regulation of state, autonomic stability, and reflex in 381 infants younger than 62 days of age. [@b82-ehp0114-000010] found a significant association between increasing total concentrations of maternal urine OP metabolites representing "approximately 80% of OPs used in the Salinas Valley" and increasing numbers of abnormal reflexes in the infants from days 3 to 62. The median age for testing the infants was day 3. Mothers' urine was tested at 14 and 26 weeks during gestation and at day 7 post-partum. The median urine levels of dialkyl phosphate (DAP), dimethyl phosphate, and diethyl phosphate, respectively, were 132, 97, and 21 mol/L during gestation and 222, 160, and 27 nmol/L after delivery. DAP represents the total of diethyl and dimethyl phosphate metabolites. The dimethyl metabolites could reflect exposure to malathion, oxydemetonmethyl, dimethoate, naled, and methidathion, and the diethyl metabolites could reflect exposure to diazinon, CPF, and disulfoton used in the Salinas Valley. It is important to keep in mind that the OPs are readily metabolized, and exposure can vary considerably and most often is transient and unpredictable. The authors noted that there were large within-person variations in urine levels in this study.

A Case Study: The Cryptic Neurodevelopmental Effects of CPF
===========================================================

The insecticide CPF is an OP pesticide that has been on the market since 1965 to control insects in agriculture, gardens, building construction, and households. In 2002 the use of CPF was restricted to only agricultural applications, and all domestic use was to be completely phased out by 1 January 2005. The metabolites of CPF have been widely reported in human tissue. In a study based on data from the Centers for Disease Control and Prevention's ([@b17-ehp0114-000010]) first *National Report on Human Exposure to Environmental Chemicals,* [@b38-ehp0114-000010] found the CPF analyte TCP in 82% of urine samples (*n* = 1,000) from a broad sample of the U.S. population between the ages of 20 and 59 years from all regions of the country. The CDC's *Second National Report on Human Exposure to Environmental Chemicals* ([@b18-ehp0114-000010]) states that the levels of TCP were similar to levels presented in the first *National Report on Human Exposure to Environmental Chemicals* ([@b17-ehp0114-000010]) but gave no statistics concerning the extent of exposure across the population. Like the other OP insecticides, CPF inhibits the enzyme acetylcholinesterase, which destroys acetylcholine, the neuro-transmitter that activates cholinergic neurons. These are an important group of nerve cells that control signals in the peripheral nervous system and in the brain and spinal cord. If acetylcholine is not inactivated immediately by the activity of acetylcholinesterase, it over-stimulates the neurons, and tremors, convulsions and death can follow.

As scientists probed deeper into the activity of CPF, a wealth of information surfaced from laboratory studies about its effects on the development and function of the brain and nervous system in embryos, fetuses, and young animals. Although many of the studies were performed on rats and there are differences in the ontogeny of specific parts of the brain between rats and humans, the development of the rat brain through postnatal day (PND) 21 provides a model for the development of the human brain through to birth.

A series of reports starting in 1991 confirmed that CPF is a cholinesterase inhibitor and that neonatal rats were more sensitive than adults when exposed to a single maximum tolerated dose ([@b58-ehp0114-000010]; [@b60-ehp0114-000010], [@b59-ehp0114-000010]). These studies also confirmed that the fetus recovers quicker than the adult from cholinesterase inhibition, suggesting that the fetus would be protected from CPF if all the adverse effects were due to cholinesterase inhibition alone. [@b47-ehp0114-000010], however, wrote that although the fetus could recover faster between repeated doses of CPF, this was only an "illusion that the fetal compartment is less affected than the maternal compartment." Realizing that something other than cholinesterase inhibition was affecting the fetus, a team from Duke University led by Theodore Slotkin gradually began to demonstrate that other mechanisms of action of CPF alter prenatal development of the brain and behavior and that the embryo and fetus are sensitive to cholinesterase inhibition at doses that would not be toxic to an adult ([@b64-ehp0114-000010]; [@b75-ehp0114-000010]). These studies provided information about how the brain develops and functions and also provided a chronology of how CPF interferes at successional stages of brain development ([@b62-ehp0114-000010]). This team also demonstrated that CPF-oxon, the active metabolite of CPF, is the compound that causes cholinesterase inhibition and that the actual neuroteratogen is CPF (see [@b75-ehp0114-000010] for a step-by-step description of how their CPF research progressed).

Slotkin and colleagues demonstrated that as the brain and nervous system are constructed and programmed, there are numerous points in time and at sites where CPF could interfere. CPF attacks the neurons that appear in the earliest stage of brain and central nervous system (CNS) development ([@b61-ehp0114-000010]). Neurons process information and are the signaling or transmitting elements in the nervous system. Damage to neurons at this early stage may not be expressed until years later. For example, a brief subtoxic dose of CPF \[1 or 5 mg/kg body weight (bw)/day\] during neurulation can cause behavioral alterations during adolescence and adulthood ([@b40-ehp0114-000010]). And, although some early symptoms of CPF exposure disappear during certain stages of development, different neurologic symptoms can appear later in life ([@b62-ehp0114-000010], [@b64-ehp0114-000010], [@b61-ehp0114-000010]).

Glial cells that appear later than neurons during early development were shown to be more vulnerable than neurons to CPF ([@b62-ehp0114-000010]; [@b67-ehp0114-000010]). There are more than twice as many glial cells (\> 200 billion) in the body than neurons. Glial cells come in many varieties; they are supportive cells critical for normal development and function and serve as a "scaffold" for migration of cells during tissue construction \[see [@b8-ehp0114-000010] on brain development\]. Glial cells also provide nutrition to the neurons and provide a link with the immune system, responding to damage by acting as scavengers of pathogens and neuronal debris. CPF preferentially targets the glial cells among the cells it attacks ([@b34-ehp0114-000010]).

Slotkin and colleagues repeatedly demonstrated that CPF toxicity is not limited to cholinesterase inhibition alone but can act by other mechanisms. For example, *in vitro* and *in vivo* studies at three levels of development from DNA to the cell and the whole animal revealed that CPF is far more toxic than previously thought because of this wider range of activity ([@b21-ehp0114-000010]). CPF impairs the binding to DNA of nuclear transcription factors (AP-1 and Sp1) that modulate cell replication and differentiation. When undifferentiated and differentiated neurons were exposed to CPF, the response of some transcription factors varied. Although the activity of one set of cells might not be affected, the activity of another set of cells might be significantly reduced. An independent study at Johns Hopkins University ([@b71-ehp0114-000010]) confirmed the ability of CPF to alter the activity of another nuclear transcription factor in cortical neurons, the Ca^2+^/cAMP response element binding protein (CREB), which is critical for cell survival and differentiation during development and is critical for memory. CPF increased the activated level of CREB at 0.01 nM, well below the level at which cholinesterase inhibition is expressed and below the typical level of human exposure. [@b71-ehp0114-000010] also demonstrated that CPF-oxon did not cause the alteration, supporting the conclusion of [@b21-ehp0114-000010] that CPF is more than a cholinesterase inhibitor. [@b21-ehp0114-000010] also demonstrated that the CPF effects on the development of the forebrain in the rat, which reaches its peak stage of development during gestation, were not as severe as the effects on the cerebellum, which reaches its peak 2 weeks after birth. The cerebellar changes in the later stages of development, however, could not have been the result of cholinesterase inhibition because the cerebellum is not innervated with cholinergic receptors like the forebrain is ([@b21-ehp0114-000010]).

Much of the research undertaken by Slotkin and colleagues demonstrated that models of adult toxicity do not extrapolate to fetuses and would not predict the vulnerability of the embryo to TCP and CPF ([@b4-ehp0114-000010], [@b1-ehp0114-000010]). The ever-changing state of the embryo makes it a more sensitive model for toxicity and a better predictor of long-term, delayed effects. Slotkin and colleagues have demonstrated that the embryo and fetus reveal innumerable mechanisms of action of toxicity that could not be detected in an adult animal. For example, in a series of *in vitro* studies, a 25% increase in reactive oxygen species (ROS) was found 10 min after undifferentiated glial C6 cells were exposed to CPF ([@b33-ehp0114-000010]). During some stages of development, selected regions of the brain are vulnerable to CPF by interference with the G-protein in the adenylyl cyclase (AC) cascade by disrupting nuclear transcription DNA binding ([@b52-ehp0114-000010]; [@b74-ehp0114-000010]). CPF caused abnormal tissue/cell development in cultured rat embryos through vacuolation of the cytoplasm ([@b66-ehp0114-000010]). CPF, CPF-oxon, and TCP inhibit DNA synthesis in PC12 cells (typical neuronal cells) and C6 cells (typical glial cells), having a greater effect on the glial cells, with the exception of the TCP ([@b63-ehp0114-000010]). [@b63-ehp0114-000010] also showed that CPF is a stronger DNA synthesis inhibitor than CPF-oxon, although it is a weaker cholinesterase inhibitor. Confirming again that certain regions of the developing brain were more susceptible than others, [@b63-ehp0114-000010] found that CPF and TCP suppress DNA synthesis in the epithelium of the forebrain and inhibit neural cell replication. These studies also revealed that serum binding proteins can be protective of DNA antimitotic activity, but because fetuses and newborns have lower concentrations of serum proteins than adults, they could be more vulnerable.

In a series of whole-animal studies looking at damage in rats from the embryo to the adult, Slotkin and colleagues demonstrated again that assays using adult animals cannot predict the long-term delayed effects in the offspring. For example, within hours after 9.5-day-old embryos were exposed to CPF, they showed clear signs of damage that was restricted to the primordial brain ([@b66-ehp0114-000010]). Upon histologic examination, [@b66-ehp0114-000010] found apoptosis and altered mitotic figures, along with gross disruption of the architecture of the developing brain, all in the absence of any gross morphologic defects in the other parts of the embryo. As these animals matured, CPF damage was demonstrable in a wide variety of brain regions. The most vulnerable target was the hippocampus, with the damage expressed both as deficits in nerve activity and as corresponding behavioral abnormalities ([@b40-ehp0114-000010]). Dosing an adult animal similarly would not have provoked these effects of fetal origin.

The complexity of the toxicity of CPF became more apparent as sex-related differences began to appear in *in vivo* assays. The sex-related changes occur when CPF exposure takes place during gestation days (GD) 17--20 (late gestation) and PND1--4 and again at PND11--14. The timing of this exposure in the rat is comparable to human brain development during the perinatal and neonatal period ([@b4-ehp0114-000010]; [@b51-ehp0114-000010]; [@b76-ehp0114-000010]). Late prenatal exposure to CPF has also been shown to cause long-term sex-specific changes in cognitive performance ([@b48-ehp0114-000010]). Adolescent and adult females were more vulnerable to CPF, based on their number of errors during working- and reference-memory tasks. [@b48-ehp0114-000010] also found profound differences between animals exposed to 1 mg/kg and 5 mg/kg CPF, reflecting a U-shaped dose curve. The lowest dose was the most potent in this case, although the highest dose caused the most inhibition of fetal brain cholinesterase. The non-monotonic dose--response curve discovered in the assay, combined with the fact that the results were not dependent on cholinesterase inhibition, raises questions about indirect effects of CPF and its metabolites on the endocrine system via the brain. However, as Slotkin (personal communication) pointed out, hormesis cannot be ruled out until further research proves otherwise. In light of their findings, [@b48-ehp0114-000010] noted the need for childhood and adolescent maturation studies and for the development of more sex-selected end points.

At a concentration somewhat higher than human exposure, 50 μg/mL CPF *in vitro* induces the release of norepinephrine from rat brain synaptosomes ([@b23-ehp0114-000010]). Studies using whole animals confirmed that the release of norepinephrine inhibits synaptogenesis, a condition that persists to adulthood and is sex specific, long after exposure ceases and cholinesterase activity is restored ([@b48-ehp0114-000010]). [@b4-ehp0114-000010] showed that CPF administered during GD9--12 up-regulated serotonin (5-hydroxytryptamine; 5-HT) receptors (5-HT-1 and 5-HT-2) and interfered with the 5-HT protein transporter from the neural tube stage through to adulthood. But during GD17--20, CPF initiated larger effects in regions with greater numbers of 5-HT nerve terminals, which were found more in males. This response continued through PND1--4. In contrast, the 5-HT protein transporter was downregulated in females ([@b4-ehp0114-000010]). [@b1-ehp0114-000010],[@b2-ehp0114-000010] performed studies demonstrating abnormalities of 5-HT--related behaviors in developing rats exposed to CPF. The research that preceded this report mapped out the ontogeny of serotonin receptors in the brainstem and forebrain ([@b3-ehp0114-000010]). The authors pointed out that serotonin disruption has been linked to appetitive and affective disorders, and the biologic significance of these findings needs to be clarified. These disorders have been the focus of increasing research attention in recent years as the result of the increasing use of prescription and and illicit mind-altering drugs.

Other Pesticide Products That Interfere with Neurodevelopment
=============================================================

There are numerous opportunities during gestation where insecticides and products from several other chemical classes can alter the purpose of a cell, tissue, organ, or system function in the brain or CNS, much like the discoveries presented for CPF.

Herbicides.
-----------

Over the past 15 years, an Argentinian research team has produced a series of reports on 2,4-D that is comparable to the research on CPF. This team discovered that exposure during lactation to the herbicide 2,4-DBE (the butyl ester of 2,4-D) can alter brain production of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in adulthood ([@b11-ehp0114-000010]; [@b30-ehp0114-000010]; [@b32-ehp0114-000010]). Concentrations of both dopamine and serotonin changed transiently if the animals were exposed only through birth (69 mg/kg bw/day from GD6 to birth; 15 days) and permanently if delivered to the offspring through breastfeeding as well from GD6 to weaning (30 days). [@b26-ehp0114-000010] and [@b65-ehp0114-000010] found that 2,4-D interfered with myelination in the brain as the result of lactational exposure. This caused changes in behavior patterns that included apathy, reduced social interaction, repetitive movements, tremors, and immobility in pups exposed to 2,4-D ([@b10-ehp0114-000010]; [@b29-ehp0114-000010]). They also discovered that the serotoninergic and dopaminergic effects occurred during postnatal brain development, similar to the effects of CPF. [@b10-ehp0114-000010] and [@b29-ehp0114-000010] also found 2,4-D in breast milk of 2,4-D--fed mothers and in the stomach content, brain, and kidney of 4-day-old pups ([@b78-ehp0114-000010]).

Insecticides.
-------------

[@b15-ehp0114-000010] reported that the lowest dose of chlordane used in their studies (100, 500, 5,000 ng/g/day both prenatally and postnatally) caused a dose-dependent reduction in testosterone levels in females in adulthood. The lowest dose they used was 10 times lower than the U.S. EPA's lowest observed adverse effect level (LOAEL) for neurologic effects (1,000 ng/g) and 50 times lower than the U.S. EPA's LOAEL for developmental effects (5,000 ng/g) of chlordane ([@b15-ehp0114-000010]). Females exhibited improved spatial abilities and auditory startle-evoked responses more similar to male responses, and slight increases in body weight. Changes in male mating behavior included shortening of latency to intromission and increased intromissions. The authors speculated that pesticides structurally similar to chlordane cause masculinization of function and behavior in both sexes because the pesticides mimic the sex steroids or change their plasma levels through other enzyme systems. The two lower doses in this study prompted greater change than the highest dose for auditory startle response, mating behavior, and body weight.

Methoxychlor (MXC), an insecticide whose toxicity depends on its conversion to several metabolites, was considered to be an estrogen for many years and only recently was discovered to have antiestrogenic and androgenic properties as well. To measure neuro-developmental impacts, [@b57-ehp0114-000010] fed pregnant CD-1 mice environmentally relevant doses of MXC (0.02, 0.2, and 2.0 μg/g mother bw/day) from GD11 to GD17 and examined them on postpartum days 2--15. Mothers fed the lowest dose spent less time nursing than the controls, possibly reflecting the inverted U-shaped dose--response curve expressed by endocrine disruptors. At late adolescence the pups exhibited a reduction in novelty seeking (both the environment and objects), with a difference between males and females ([@b56-ehp0114-000010]). Male sexual aggression was reduced at puberty but returned to normal in adulthood. The reduction in aggressive behavior in the periadolescent male CD-1 mouse as a result of MXC exposure (20 μg/kg/day) occurred at a dose 100 times lower than the dose at which the Agency for Toxic Substances and Disease Registry ([@b7-ehp0114-000010]) deemed would cause no harm to humans in 1994. The ATSDR recently withdrew this minimum risk level in light of new evidence on MXC.

Dopaminergic neurons in the substantia nigra project to and release dopamine to the corpus striatum of the brain. This section of the brain integrates neuromuscular and behavioral information and is involved in the control of locomotor activity, exploration, and novelty-induced behavior. It also influences social--sexual interactions such as aggression and maternal behavior. The loss of dopamine function in the neurons connecting the corpus striatum with the midbrain of humans is the cause of Parkinson disease. Male offspring of mice exposed to 20 μg/kg/day MXC had fewer dopaminelike receptors in their corpus striatum and were less active than control females ([@b80-ehp0114-000010]). Females exposed to the same concentrations showed a malelike profile in reactivity to novelty. Similar changes in males and females were seen in mice exposed to *o,p*′-DDT in the same study. In an unrelated study, [@b46-ehp0114-000010] discovered increased locomotor behavior in offspring of Sprague-Dawley rats administered 0.5 mg/kg/day MXC throughout gestation.

Prenatal exposure to aldrin also causes delayed neurologic impairment that extends through to adulthood. [@b16-ehp0114-000010] administered 1 mg/kg aldrin subcutaneously to female rats daily from conception to birth and tested their pups on PND1--2 and again on PND90. On PND90, the animals showed loss of locomotor control and behavioral change(s). Aldrin was not measurable in the animals at the time they were tested.

Paraoxon is the oxidized metabolite of parathion and a potent OP cholinesterase inhibitor. Chronic paraoxon exposure (0.1, 0.15, or 0.2 mg/kg subcutaneously) during a stage of rapid cholinergic brain development from PND8 to PND20 in male Wistar rats led to reduced dendritic spine density in the hippocampus without obvious toxic cholinergic signs in any of the animals ([@b68-ehp0114-000010]). Some animals in the two highest dose groups died in the early days of the study. All doses caused retarded perinatal growth, and brain cholinesterase activity was reduced 60% by PND21.

[@b42-ehp0114-000010] showed that a single exposure to a pesticide before or shortly after birth can sensitize the offspring to low doses of other pesticides later in life, even though there are no immediate changes in the structure and function of the nervous system at the time of exposure. Only as the exposed individual matures do irreversible alterations in structure and function become evident. The researchers exposed mice to one dose of DDT (0.5 mg/kg bw orally) on PND10 and then at 5 months of age exposed them to bioallethrin (0.7 mg/kg bw) ([@b42-ehp0114-000010]) or paraoxon (0.7 or 1.4 mg/kg bw) for 7 days ([@b43-ehp0114-000010]). When tested 2 months later, at 7 months of age, the offspring exhibited changes in spontaneous behavior and cholinergic muscarinic receptor density in the cerebral cortex, which led to impairment in learning and memory ([@b28-ehp0114-000010]). Again, the neurodevelopmental damage was not seen immediately, but instead took 2 months to be expressed. PND10 in the mouse is equivalent to the end of the second trimester in the human. It is during this stage, from the third trimester of pregnancy through 2 years of age in humans, when the neurotransmitter system in the CNS goes through a growth spurt ([@b27-ehp0114-000010]). Throughout these studies the animals showed no clinical signs of toxic symptoms, and the doses used for adult treatment in these studies had no immediate effect on the adult. The dose of DDT used in this study is in the range that human infants might be exposed to during lactation today ([@b77-ehp0114-000010]). Even though the functional and structural outcomes in the above studies are similar, it should be remembered that they were caused by different mechanisms. For example, bioallethrin causes harm by prolonging sodium channel openings, whereas paraoxon inhibits acetylcholinesterase activity; but they both caused similar neuronal changes, which raises questions about the combined effects of pesticide mixtures on development. These studies support the premise that the differences in susceptibility of adults to pesticides may not be genetic, but rather that susceptibility to pesticides can be acquired by low-dose pesticide exposure earlier in life.

Insecticide and acaricide.
--------------------------

Rat pups displayed deficits in learning and retention of memory after exposure to the organochlorine insecticide and acaricide endosulfan (6 mg/kg bw) on PND2--25 ([@b45-ehp0114-000010]). The concentrations of the neurotransmitters, noradrenalin, dopamine, and serotonin in the olfactory bulb, hippocampus, visual cortex, brainstem, and cerebellum either increased or decreased depending on the days of examination, PND10 and PND25. The authors ruled out acetylcholinesterase inhibition as the cause of the alterations in the production of the neurotransmitters because they found no differences in acetylcholine activity in any of the regions of the brain used in the study. They suggested that endosulfan directly led to a "re-altering" of the construction of those parts of the brain. By PND25, as the differentiation and organization of the observed tissues proceeded in the presence of endosulfan, the rats' performance became significantly compromised.

Fungicides.
-----------

[@b36-ehp0114-000010] provided an excellent overview of how prenatal exposure to a fungicide can alter sexual behavior and function in adulthood, even though growth and viability are not compromised. The neurobehavioral alterations quantified in the studies they reviewed include activity level, aggression, mounting frequency, and completed intromissions. In a study using the fungicide vinclozolin, [@b37-ehp0114-000010] reported that 100% of the exposed males failed to attain intromission, although there was no reduction in mounting behavior. In subsequent studies, newborn male and female rats were injected on PND2 and PND3 with 200 mg/kg vinclozolin and observed for social behavior on PND36 and PND37 ([@b39-ehp0114-000010]). Both males and females exhibited changes in play behavior. Females became involved in increased rough-and-tumble play, a behavior imprinted by male hormones in the brain during early development. Conversely, the males' rough-and-tumble play was reduced, and they behaved more like unexposed females. Because only one dose was used, this study does not indicate the lowest dose needed to initiate these changes. More recently, on PND34 [@b19-ehp0114-000010] found significantly increased nape contact, pounce, pin, and wrestle play behavior in male offspring of females exposed to 6 and 12 mg/kg bw/day vinclozolin from GD14 to PND3. At a maternal dose of 1.5 mg/kg bw/day vinclozolin, there was a significant increase in penile dysfunction in adulthood. Future studies should include more than one dose, preferably over several orders of magnitude, to take into account the susceptibility and sensitivity of the developing animal.

Discussion
==========

There is a great deal of uncertainty about the neurodevelopmental effects of pesticides among the human studies presented here. Exposure has become too complex because of the hundreds of pesticide active ingredients on the market, confounded by background exposure to industrial chemicals that share similar effects. In addition, functional changes are expressed over a continuum, making it difficult to document the damage which often is expressed as more than one lesion and at different intervals or stages of development. The pesticides discussed here, with the exception of DDT, are still widely used in the United States despite these data. Although this information is available, the U.S. EPA has rarely used the open literature in its risk assessments, generally using only data submitted by manufacturers. Industry continues to use traditional toxicologic protocols that test for cancer, reproductive outcome, mutations, and neurotoxicity, all crude end points in light of what is known today about functional end points. In using manufacturer data, the U.S. EPA misses almost all delayed developmental, morphologic, and functional damage of fetal origin and, in the case of CPF and all OPs, continues to rely primarily on blood cholinesterase inhibition data in risk assessments ([@b83-ehp0114-000010]). The U.S. EPA should accept nonguideline, open literature to determine the toxicity of a chemical. For example, [@b14-ehp0114-000010] published a comprehensive review of the open literature in which she found 63 pesticides that interfere with the thyroid system---a system known for more than a century to control brain development, intelligence, and behavior. Yet, to date, the U.S. EPA has never taken action on a pesticide because of its interference with the thyroid system.

It would be difficult to find another pesticide in use today that has been as systematically studied as CPF. The amazing litany of diverse mechanisms discovered in the series of CPF studies raises serious questions about the safety of not only CPF and the other OPs but all pesticides in use today. Most astounding is the fact that a large part of CPF's toxicity is not the result of cholinesterase inhibition, but of other newly discovered mechanisms that alter the development and function of a number of regions of the brain and CNS. These findings send a warning that even though an OP pesticide like CPF may have a very high EC~50~ (concentration that produces 50% of the maximum possible effective response) for acute toxicity as a result of cholinesterase inhibition, it may have other toxic strategies that are far more egregious than cholinesterase inhibition. This raises a question about the value of using EC~50~ values if they do not represent the most sensitive end point. [@b64-ehp0114-000010] warn that "developmental neurotoxicity consequent to fetal or childhood CPF exposure may occur in settings in which immediate symptoms of intoxification are absent." They also point out that in the case of CPF, damage is not always global (referring to the entire brain) but may only interfere in specific regions of the brain during development, which could increase the difficulty of detecting the damage. S.J. [@b32-ehp0114-000010] state that "measurement just of cholinesterase activity is a questionable approach in assigning an appropriate index of safety."

The knowledge gained from a decade of the CPF/brain studies by Slotkin and colleagues and the 2,4-D/brain studies by Evangelista de Duffard and co-workers not only demonstrates the insidious nature of CPF and 2,4-D exposure, but it also demonstrates the weaknesses in current standard practices for determining the safety of a pesticide or any other synthetic chemical. These discoveries demonstrate that a much larger battery of tests must be used when determining the safety of commercial pesticides. Even a U.S. EPA analysis of developmental neurotoxicity studies stated that the U.S. EPA's current developmental neurotoxicologic testing protocol is "not a sensitive indicator of toxicity to the offspring" and urged the U.S. EPA "to further consider if it will use literature data" ([@b49-ehp0114-000010]). In this case, "literature data" refers to all of the peer-reviewed reports concerning the pesticide impacts on neuro-development that heretofore have not been used for risk assessment by the agency. In the case of CPF and 2,4-D, it appears that those who reviewed the data failed to understand its significance or had other reasons to ignore it. The U.S. EPA needs to convene a panel of independent experts to review these studies for applicability to determine if and how they can be used for registration.

Laboratory studies have clearly revealed neurologic damage after exposure to specific pesticides and in some studies at concentrations equivalent to ambient exposure. Even so, the animal testing for regulatory purposes that takes place today does not attempt to detect adverse health effects at the concentrations at which humans are exposed. Instead, the highest concentrations of chemicals tested are those that can be used without killing the animals or reducing the test mother's weight and her reproductive ability. In most animal studies the pesticides are administered at high oral or subcutaneous doses orally, not reflecting that, for most humans and wildlife, exposure could in many instances be dermal or via inhalation and, in many cases, over a long period of time at low doses. The U.S. EPA currently requires chronic toxicity studies, but it is locked into using high doses to elicit effects and has not overcome the difficulty of detecting effects from chronic or ambient exposure or low doses. In addition, the human pharmacokinetics of pesticide exposure can either enhance or reduce the health impacts depending on individual variations. In some cases the major or minor metabolites are more toxic than the parent compound, which is listed as the active ingredient.

In a recent study, [@b12-ehp0114-000010] found a different profile of developmental neurotoxicity between polychlorinated biphenyls (PCBs; such as Aroclor 1254) alone and with a mixture of organochlorine pesticides. Very low doses of the chemicals together delayed ear opening, affected geotaxis, and reduced grip strength. Ultimately, mortality, growth, thyroid function, and neurobehavioral development were affected. It is safe to say that there are very few people in the developed world today who are not carrying PCBs in their bodies. If animal testing continues to be used for determining the safety of pesticides, at least one group of the test animals should be exposed to PCBs before testing the pesticides for their ability to cause unpredictable interactive effects such as those described above.

It should be pointed out that the same signaling systems (AC cAMP) involved in the sex-selective changes in brain development have also been shown to alter heart and liver function in adulthood ([@b51-ehp0114-000010], [@b53-ehp0114-000010]). The AC system is ubiquitous throughout the body. In the future, the most efficient, comprehensive assays will take advantage of the fact that most chemicals have more than one effect in one system. Cross-disciplinary teams will be required to design these assays so that every organ system is carefully screened for damage. And most important, this will reduce by thousands the numbers of animals needed for testing. However, improved neurodevelopmental tests with laboratory animals will not fulfill their greatest potential if they are not backed up by better batteries of tests to detect functional disabilities in children. Such new, sophisticated quantitative tests are now available and are being updated regularly. These tests go beyond diagnostic testing to "performance evaluation" and are designed to detect the subtle effects of chronic, low-dose exposure ([@b24-ehp0114-000010]).

In conclusion, an entirely new approach to determine the safety of pesticides is needed. It is evident that contemporary acute and chronic toxicity studies are not protective of future generations. The range of doses used in future studies must be more realistic, based on levels found in the environment and human tissue. In this new approach, functional neurologic and behavioral end points should have high priority, as well as the results published in the open literature. In every instance, the impacts of transgenerational exposure on all organ systems must be meticulously inventoried through two generations on all contemporary-use pesticides and new pesticide coming on the market. To protect human health, however, a new regulatory approach is also needed that takes into consideration this vast new knowledge about the neurodevelopmental effects of pesticides, not allowing the uncertainty that accompanies scientific research to serve as an impediment to protective actions.
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